Alnylam Pharmaceuticals (ALNY) Cash from Operations (2009 - 2026)

Alnylam Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 70504000.0 for Q1 2026.

• Quarterly Cash from Operations rose 158.6% year-over-year to 70504000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 714896000.0 (up 1617.54% YoY) and the FY2025 annual result came in at 524080000.0, up 6405.1% from the prior year.
• Cash from Operations was 70504000.0 for Q1 2026 at Alnylam Pharmaceuticals, down from 163555000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 359412000.0 in Q3 2023 and bottomed at 171193000.0 in Q1 2022.
• A 5-year average of 8773764.71 and a median of 58986000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations sank 217.71% — and 2025, when it surged 643.84%.
• Alnylam Pharmaceuticals' Cash from Operations stood at 131978000.0 in 2022, then surged by 77.42% to 29795000.0 in 2023, then sank by 217.71% to 94662000.0 in 2024, then soared by 272.78% to 163555000.0 in 2025, then tumbled by 56.89% to 70504000.0 in 2026.
• Business Quant data shows ALNY's Cash from Operations at 70504000.0 in Q1 2026, 163555000.0 in Q4 2025, and 325109000.0 in Q3 2025.